HealthNotableSingle-source
5.0
Costa Rica drug access lag hits 7.3 years, above regional average
El FinancieroLO·CR·2 days ago
HealthSingle-sourceMedium
4.8
UCB secures US accelerated review for Cimzia, extending flagship drug's lifecycle
UCB announced an accelerated review procedure in the US for Cimzia (certolizumab pegol), its flagship drug that generated €1.95B last year before being surpassed by Bimzelx. The accelerated review likely covers a new indication or formulation, though specifics are undisclosed. This move aims to extend the product's commercial viability amid competition and patent pressures.
Score Breakdown
Mosaic Score4.8
Confidence0.5
Significance0.5
Source credibility0.3
Related signals
8 foundHealthNotablePartialDeveloping
7.1
Iran pharmacy debt crisis: 77T toman insurance shortfalls disrupt drug supply
IranWire·IR·2 days ago
EnergyHighSingle-sourceBuilding
6.7
Belgian Nuclear Restart at Risk: Doel 3, Tihange 2 Vessel Samples Raise Doubts
Le SoirLO·BE·about 17 hours ago
MarketsNotableConfirmedDeveloping
6.3
Banco Master Secrecy Breach Hits Brazilian Assets; Ibovespa Falls, Dollar Rises
Valor Econômico·BR·about 4 hours ago
EnergyNotableSingle-sourceDeveloping
5.1
Bluecore Advances Floating Nuclear Power Project at Port of Long Beach
gCaptain·US·1 day ago
MarketsNotableSingle-source
5.1
NBP designates BLIK systemically important payment system in Poland
ParkietLO·PL·1 day ago
MarketsNotableSingle-source
5.1
Nordnet rebuked by Swedish FSA for undisclosed influencer marketing of day trading
E24LO·SE·3 days ago
TechNotableSingle-source
5.0
Citi survey: US pharma execs skeptical AI will improve drug success rates
South China Morning PostLO·US · CN·3 days ago